NZ629728A - Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use - Google Patents
Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of useInfo
- Publication number
- NZ629728A NZ629728A NZ629728A NZ62972813A NZ629728A NZ 629728 A NZ629728 A NZ 629728A NZ 629728 A NZ629728 A NZ 629728A NZ 62972813 A NZ62972813 A NZ 62972813A NZ 629728 A NZ629728 A NZ 629728A
- Authority
- NZ
- New Zealand
- Prior art keywords
- pharmaceutical compositions
- methods
- morpholinoalkyl
- disease
- fumarate compounds
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 title 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- -1 fumarate HCl salt Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261595835P | 2012-02-07 | 2012-02-07 | |
| PCT/US2013/025118 WO2013119791A1 (en) | 2012-02-07 | 2013-02-07 | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ629728A true NZ629728A (en) | 2016-07-29 |
Family
ID=47720772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ629728A NZ629728A (en) | 2012-02-07 | 2013-02-07 | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8952006B2 (https=) |
| EP (1) | EP2812319A1 (https=) |
| JP (1) | JP5918395B2 (https=) |
| KR (1) | KR20140129136A (https=) |
| CN (1) | CN104169261A (https=) |
| AU (1) | AU2013203335B2 (https=) |
| BR (1) | BR112014019480A8 (https=) |
| CA (1) | CA2864040A1 (https=) |
| IL (1) | IL233941A0 (https=) |
| MX (1) | MX2014009511A (https=) |
| NZ (1) | NZ629728A (https=) |
| RU (1) | RU2014136394A (https=) |
| TW (1) | TWI486339B (https=) |
| WO (1) | WO2013119791A1 (https=) |
| ZA (1) | ZA201406145B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20140640T1 (hr) | 2008-08-19 | 2014-11-21 | Xenoport, Inc. | Prolijekovi monometil estera fumarne kiseline, farmaceutski sastavi iz toga i postupci njihove uporabe |
| WO2013181451A1 (en) * | 2012-05-30 | 2013-12-05 | Xenoport, Inc. | Treatment of multiple sclerosis and psoriasis using prodrugs of methyl hydrogen fumarate |
| WO2014031901A1 (en) * | 2012-08-22 | 2014-02-27 | Xenoport, Inc. | Methods of use for monomethyl fumarate and prodrugs thereof |
| US10945984B2 (en) | 2012-08-22 | 2021-03-16 | Arbor Pharmaceuticals, Llc | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| AU2013305684B2 (en) | 2012-08-22 | 2016-11-24 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| AR094277A1 (es) * | 2012-12-21 | 2015-07-22 | Biogen Idec Inc | Derivados de fumarato sustituidos con deuterio |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| BR112015022854A2 (pt) | 2013-03-14 | 2017-07-18 | Alkermes Pharma Ireland Ltd | pró-farmacos de fumaratos e uso do mesmo no tratamento de várias doenças |
| WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
| WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
| WO2014205392A1 (en) | 2013-06-21 | 2014-12-24 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| EP3041467A1 (en) | 2013-09-06 | 2016-07-13 | XenoPort, Inc. | Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use |
| WO2015043688A1 (en) * | 2013-09-27 | 2015-04-02 | Ratiopharm Gmbh | Prodrugs of monomethyl fumarate (mmf) |
| ES2651962T3 (es) * | 2013-12-05 | 2018-01-30 | Ratiopharm Gmbh | Derivados de bis-MMF |
| JP6337135B2 (ja) | 2014-02-24 | 2018-06-06 | アルカーメス ファーマ アイルランド リミテッド | フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用 |
| ES2718548T3 (es) | 2014-03-21 | 2019-07-02 | Univ Paris Val De Marne | Híbridos de molécula de liberación de CO-fumarato, su utilización en el tratamiento de enfermedades inflamatorias o cardiovasculares y su procedimiento de preparación |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| WO2016061393A1 (en) | 2014-10-15 | 2016-04-21 | Xenoport, Inc. | Fumarate compounds, pharmaceutical compositions, and methods of use |
| US10170537B2 (en) | 2014-12-23 | 2019-01-01 | International Business Machines Corporation | Capacitor structure compatible with nanowire CMOS |
| US9630934B2 (en) * | 2015-02-08 | 2017-04-25 | Mark Quang Nguyen | Fumarate compounds, pharmaceutical compositions thereof, and methods of use |
| BR112017025499A2 (pt) | 2015-05-28 | 2018-08-07 | Baylor College Medicine | benefícios da suplementação com n-acetil cisteína e glicina para melhorar os níveis de glutationa |
| WO2019042301A1 (zh) * | 2017-08-29 | 2019-03-07 | 浙江海正药业股份有限公司 | (E)-α,β-不饱和酰胺化合物及其制备方法和用途 |
| CN116307280B (zh) * | 2023-05-18 | 2023-08-01 | 成都理工大学 | 一种酸性气藏气井储层硫堵损伤量化评估方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2163060A1 (de) * | 1971-12-18 | 1973-06-20 | Basf Ag | Waesserige dispersionen von mischpolymerisaten von monoestern olefinisch ungesaettigter dicarbonsaeuren |
| DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| DE19814358C2 (de) | 1998-03-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn |
| DE19839566C2 (de) | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
| DE19848260C2 (de) | 1998-10-20 | 2002-01-17 | Fumapharm Ag Muri | Fumarsäure-Mikrotabletten |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| DE10000577A1 (de) | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
| HU230252B1 (hu) | 2001-01-12 | 2015-11-30 | Biogen Idec International Gmbh | Fumársav-amid származékok |
| DE10101307A1 (de) | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| DE10217314A1 (de) | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
| GB0320441D0 (en) * | 2003-09-02 | 2003-10-01 | Givaudan Sa | Organic compounds |
| SI1663197T1 (sl) | 2003-09-09 | 2008-06-30 | Biogen Idec Internat Gmbh | Uporaba derivatov fumarne kisline za zdravljenje sräśne insuficience in astme |
| DE10342423A1 (de) | 2003-09-13 | 2005-04-14 | Heidland, August, Prof. Dr.med. Dr.h.c. | Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden |
| LT2801354T (lt) | 2004-10-08 | 2017-06-26 | Forward Pharma A/S | Kontroliuojamo atpalaidavimo farmacinės kompozicijos, apimančios fumaro rūgšties esterį |
| US20080004344A1 (en) | 2004-11-10 | 2008-01-03 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
| DE102005022845A1 (de) | 2005-05-18 | 2006-11-23 | Fumapharm Ag | Thiobernsteinsäurederivate und deren Verwendung |
| US20080299196A1 (en) | 2005-10-07 | 2008-12-04 | Aditech Pharma Ab | Controlled Release Pharmaceutical Compositions Comprising a Fumaric Acid Ester |
| CN101304732A (zh) * | 2005-10-07 | 2008-11-12 | Adi技术制药股份公司 | 包含富马酸酯的控释药物组合物 |
| JP5230610B2 (ja) | 2006-05-05 | 2013-07-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 二価ｓｍａｃ模倣物およびその使用 |
| HRP20140640T1 (hr) | 2008-08-19 | 2014-11-21 | Xenoport, Inc. | Prolijekovi monometil estera fumarne kiseline, farmaceutski sastavi iz toga i postupci njihove uporabe |
| JP5771627B2 (ja) * | 2010-01-08 | 2015-09-02 | カタバシス ファーマシューティカルズ，インコーポレイテッド | 脂肪酸フマル酸塩誘導体およびそれらの使用 |
| US9868690B2 (en) | 2012-12-21 | 2018-01-16 | Ratiopharm Gmbh | Prodrugs of monomethyl fumarate (MMF) |
-
2013
- 2013-02-07 MX MX2014009511A patent/MX2014009511A/es unknown
- 2013-02-07 AU AU2013203335A patent/AU2013203335B2/en not_active Ceased
- 2013-02-07 EP EP13704701.5A patent/EP2812319A1/en not_active Withdrawn
- 2013-02-07 KR KR20147025151A patent/KR20140129136A/ko not_active Abandoned
- 2013-02-07 US US13/761,864 patent/US8952006B2/en not_active Expired - Fee Related
- 2013-02-07 CA CA2864040A patent/CA2864040A1/en not_active Abandoned
- 2013-02-07 CN CN201380014174.7A patent/CN104169261A/zh active Pending
- 2013-02-07 JP JP2014556656A patent/JP5918395B2/ja not_active Expired - Fee Related
- 2013-02-07 TW TW102104764A patent/TWI486339B/zh not_active IP Right Cessation
- 2013-02-07 WO PCT/US2013/025118 patent/WO2013119791A1/en not_active Ceased
- 2013-02-07 RU RU2014136394A patent/RU2014136394A/ru not_active Application Discontinuation
- 2013-02-07 NZ NZ629728A patent/NZ629728A/en not_active IP Right Cessation
- 2013-02-07 BR BR112014019480A patent/BR112014019480A8/pt not_active IP Right Cessation
- 2013-08-14 US US13/967,283 patent/US20140051705A1/en not_active Abandoned
-
2014
- 2014-08-04 IL IL233941A patent/IL233941A0/en unknown
- 2014-08-21 ZA ZA2014/06145A patent/ZA201406145B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5918395B2 (ja) | 2016-05-18 |
| US20130203753A1 (en) | 2013-08-08 |
| BR112014019480A2 (https=) | 2017-06-20 |
| AU2013203335B2 (en) | 2016-05-26 |
| ZA201406145B (en) | 2016-06-29 |
| MX2014009511A (es) | 2014-10-24 |
| RU2014136394A (ru) | 2016-03-27 |
| IL233941A0 (en) | 2014-09-30 |
| CN104169261A (zh) | 2014-11-26 |
| CA2864040A1 (en) | 2013-08-15 |
| TWI486339B (zh) | 2015-06-01 |
| BR112014019480A8 (pt) | 2017-07-11 |
| AU2013203335A1 (en) | 2013-08-22 |
| US20140051705A1 (en) | 2014-02-20 |
| JP2015508073A (ja) | 2015-03-16 |
| EP2812319A1 (en) | 2014-12-17 |
| KR20140129136A (ko) | 2014-11-06 |
| TW201343634A (zh) | 2013-11-01 |
| US8952006B2 (en) | 2015-02-10 |
| WO2013119791A1 (en) | 2013-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ629728A (en) | Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use | |
| PH12014501029A1 (en) | Pharmaceutical compositions comprising glitazones and nrf2 activators | |
| MX2015011676A (es) | Inhibidores de leucotrieno a4 hidrolasa. | |
| FR3000601B1 (fr) | Procede de formation des espaceurs d'une grille d'un transistor | |
| SG10202010665YA (en) | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders | |
| LT3269716T (lt) | Nauji junginiai ir jų farmacinės kompozicijos, skirtos uždegiminių sutrikimų gydymui | |
| KR102297388B9 (ko) | 대사장애를 치료하기 위한 아커만시아의 용도 | |
| LU92314B1 (fr) | Procédé de réhabilitation d'un ouvrage présentant une fissure par suivi d'une courbe représentative de l'écartement des bords de la fissure | |
| GEP20186864B (en) | Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders | |
| FR3023971B1 (fr) | Procede de formation des espaceurs d'une grille d'un transistor | |
| EP2858652A4 (en) | Multi-stage process for the production of an immunomodulatory agent | |
| EP3050979A4 (en) | METHOD FOR PRODUCING A CORNORIENTED ELECTROMAGNETIC STEEL PLATE | |
| FR3013895B1 (fr) | Procede de formation des espaceurs d'une grille d'un transistor | |
| MX2015011677A (es) | Inhibidores de leucotrieno a4 hidrolasa. | |
| PH12017501043A1 (en) | 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
| EP2903643A4 (en) | TREATMENT OF PSYCHIATRIC DISEASES | |
| EP2841080A4 (en) | COMPOSITION FOR THE TREATMENT OF METABOLISM DISORDERS | |
| MX2016000724A (es) | Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas. | |
| EP3323788A4 (en) | METHOD FOR PRODUCING OXID PARTICLES | |
| FR2999572B1 (fr) | Procede de production d'acrylate d'alkyle. | |
| TN2016000197A1 (en) | Novel methods for treating neurodegenerative diseases. | |
| IN2015DN00345A (https=) | ||
| FR3002771B1 (fr) | Procede de production d'acrylate de 2-propyl heptyle par transesterefication | |
| FR3007405B1 (fr) | Procede de preparation d'une composition comprenant des particules silico/germano-metalliques fonctionnalisees et composition obtenue | |
| EP2958899A4 (en) | METHOD FOR PRODUCING A PYRIDAZINONE COMPOUND AND INTERMEDIATE PRODUCTS THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |